Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: RVMD stock price vs EVRG: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EVRG's multiple
Needs EVRG P/S.
Implied fair value · at RVMD's multiple
Needs RVMD P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RVMD FY 2023 (ended Dec 31, 2023) · EVRG FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Evergy, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.11x
1.31x
Net debt / EBITDA
Leverage against operating earnings
3.85x
4.41x
Cash and equivalents
Liquid reserves on the balance sheet
$1.85B
$19.80M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
RVMD vs AMGN
BRISTOL MYERS SQUIBB CO
RVMD vs BMY
GILEAD SCIENCES, INC.
RVMD vs GILD
INCYTE CORP
RVMD vs INCY
VERTEX PHARMACEUTICALS INC / MA
RVMD vs VRTX
Moderna, Inc.
RVMD vs MRNA
NEXTERA ENERGY INC
RVMD vs NEE
Duke Energy CORP
RVMD vs DUK
AMERICAN ELECTRIC POWER CO INC
RVMD vs AEP
XCEL ENERGY INC
RVMD vs XEL
PPL Corp
RVMD vs PPL
NRG ENERGY, INC.
RVMD vs NRG
$193.93M
$13.41B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
